Pharma-Bio Serv, Inc.

Pharma-Bio Serv, Inc.

Pharma-Bio Serv was founded in 1999 by former executives of Pharmstandard, Russia's largest pharmaceutical manufacturer. The company initially focused on clinical trial support and regulatory submission services for Western drugmakers entering the Russian market. Its founders leveraged deep ties in Russian healthcare, building a business that provided end-to-end drug development services. The firm operates across clinical research, biostatistics, data management, and regulatory compliance. It has worked with over 50 pharmaceutical clients, including Bristol-Myers Squibb, Pfizer, and Novartis (per public filings, 2020). Services span Phase I–IV clinical trials, medical writing, and pharmacovigilance. Geographic coverage includes Russia, Ukraine, Belarus, Kazakhstan, and other CIS countries. Pharma-Bio Serv employs roughly 200 professionals across its Moscow headquarters and regional offices. In 2020, the company reported annual revenues of about $15 million (per public filings, 2020). It operates as a publicly traded entity on the Moscow Exchange under ticker PHBS, with a market capitalization around $30 million as of early 2023. Pharma-Bio Serv's structural differentiator is its specialization in Russian and CIS regulatory environments, an arena few Western CROs navigate efficiently. The firm's founders maintained operational control through a dual-share structure, with Class A shares held by management carrying 10 times the voting power of public Class B shares, ensuring strategic continuity.